| Bioactivity | Sapacitabine is an orally available nucleoside analog prodrug that is structurally related to cytarabine. | ||||||||||||
| Invitro | Concentrations of Sapacitabine required to achieve an IC50 range from 3±0.6 μM for the colon cancer cell line HCT116 to 67±14 μM for the breast cancer cell line MDA-MB-435. Cell cycle analysis shows that 35% Sapacitabine-treated cells are arrested in late-S phase and 41% in G2/M phase. L1210 cells with deoxycytidine kinase (dCK) activity are sensitive to Sapacitabine, (IC50 20±6 μM). In the docetaxel/Sapacitabine combinations, synergistic effects (CI<1) are observed when docetaxel is given before Sapacitabine in both cell lines[1]. | ||||||||||||
| Name | Sapacitabine | ||||||||||||
| CAS | 151823-14-2 | ||||||||||||
| Formula | C26H42N4O5 | ||||||||||||
| Molar Mass | 490.64 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|